Neurovation Labs Raises Seed Funding

neurovation_labsNeurovation Labs, Inc., a New York, NY-based biotech company, raised a seed funding round of undisclosed amount.

This round was completed with the support of individual angel investors based in the United States.

Founded in 2016 based on the research performed by Dr. Jennifer Perusini, CEO, and Dr. Michael Fanselow, Director of Research, Neurovation Labs is an early stage biotechnology company focused on diagnosing and treating anxiety disorders and in particular Post-traumatic Stress Disorder (PTSD), an incapacitating disorder that currently has no objective diagnostic and ineffective treatment options.

The company intends to use the funds to further the development of its patent-pending PTSD diagnostic, commencing the next set of pre-clinical studies next month, testing the efficacy of using radiological imaging technology to diagnose PTSD.



Join the discussion